U.S. Patent and Trademark Office extends extortion of Clearmind’s proprietary MEAI and expands its imaginable market
Tel Aviv, Israel / Vancouver, Canada, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” oregon the "company"), a biotech institution focused connected find and improvement of caller psychedelic-derived therapeutics to lick large nether treated wellness problems, announced that it has been granted a patent from the United States Patent and Trademark Office (USPTO) for the usage of its proprietary MEAI arsenic an alcoholic beverage substitute.
Similar patents person already been granted to Clearmind for the MEAI-based intoxicant substitute successful Europe and India.
The development–U.S. Patent No. 11,077,072 B2 – is simply a large milestone, fixed the expanding popularity and maturation successful income of non-alcoholic wine, brew and spirits. According to the accusation services steadfast NielsenIQ, the marketplace for specified non-alcoholic beverages successful the U.S. successful August 2022 stood astatine $395 cardinal per year, showing a year-on-year maturation of +20.6%.
"This patent is fantabulous quality arsenic we proceed to fortify and widen the extortion astir our innovative compounds, reflecting the increasing U.S. designation of our innovative portfolio," said Dr. Adi Zuloff-Shani, Clearmind's CEO. “It’s a tremendous boost, arsenic the U.S. is 1 of the biggest markets for intoxicant substitutes.”
“This affirmative momentum confirms the worth of the innovative R&D attack that underpins our concern strategy. It strengthens our prospects for a caller ample market, antithetic from the pharma marketplace and with short-term imaginable for sizeable gross generation.” Zuloff-Shani added.
The patent follows the assignment of erstwhile Red Bull Canada enforcement Nicholas Kadysh arsenic peculiar advisor connected the regulatory improvement of MEAI arsenic an intoxicant substitute. Kadysh, who besides antecedently worked astatine Juul Labs Canada, is simply a vocation adept connected navigating analyzable regulatory risks successful the wellness and nutrient industry. He is the laminitis of PharmAla Biotech, which manufactures MDMA- and MDXX people molecules for pharmaceutical research, and the Board Chair of Psychedelics Canada, the commercialized relation of the for-profit Canadian psychedelics industry.
About Clearmind Medicine Inc.
Clearmind is simply a psychedelic pharmaceutical biotech institution focused connected the find and improvement of caller psychedelic-derived therapeutics to lick wide and underserved wellness problems, including intoxicant usage disorder. Its superior nonsubjective is to probe and make psychedelic-based compounds and effort to commercialize them arsenic regulated medicines, foods oregon supplements.
The Company’s intelligence portfolio presently consists of 7 patent families. The Company intends to question further patents for its compounds whenever warranted and volition stay opportunistic regarding the acquisition of further intelligence spot to physique its portfolio.
Shares of Clearmind are listed for trading connected Nasdaq nether the awesome "CMND", the Canadian Securities Exchange nether the awesome "CMND" and the Frankfurt Stock Exchange nether the awesome “CWY”.
For further accusation visit: https://www.clearmindmedicine.com oregon contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This property merchandise contains “forward-looking statements” wrong the meaning of the Private Securities Litigation Reform Act and different securities laws. Words specified arsenic “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and akin expressions oregon variations of specified words are intended to place forward-looking statements. For example, the Company is utilizing forward-looking statements erstwhile it discusses its patent portfolio, concern strategy, and the company’s prospects for a caller ample market, antithetic from the pharma marketplace and with short-term imaginable for gross generation. Forward-looking statements are not humanities facts, and are based upon management’s existent expectations, beliefs and projections, galore of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed successful bully faith. However, determination tin beryllium nary assurance that management’s expectations, beliefs and projections volition beryllium achieved, and existent results whitethorn disagree materially from what is expressed successful oregon indicated by the forward-looking statements. Forward-looking statements are taxable to risks and uncertainties that could origin existent show oregon results to disagree materially from those expressed successful the forward-looking statements. For a much elaborate statement of the risks and uncertainties affecting the Company, notation is made to the Company’s reports filed from clip to clip with the Securities and Exchange Commission (“SEC”), including, but not constricted to, the risks elaborate successful the Company’s last prospectus (registration No. 333-265900) filed with the SEC connected November 16, 2022. Forward-looking statements talk lone arsenic of the day the statements are made. The Company assumes nary work to update forward-looking statements to bespeak existent results, consequent events oregon circumstances, changes successful assumptions oregon changes successful different factors affecting forward-looking accusation but to the grade required by applicable securities laws. If the Company does update 1 oregon much forward-looking statements, nary inference should beryllium drawn that the Company volition marque further updates with respect thereto oregon with respect to different forward-looking statements. References and links to websites person been provided arsenic a convenience, and the accusation contained connected specified websites is not incorporated by notation into this property release. Clearmind is not liable for the contents of third-party websites.
English (US)